Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytosorbents (CTSO) Finished Goods (2023 - 2026)

Cytosorbents filings provide 3 years of Finished Goods readings, the most recent being $3.5 million for Q4 2025.

  • On a quarterly basis, Finished Goods rose 112.53% to $3.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.5 million, a 112.53% increase, with the full-year FY2025 number at $3.5 million, up 112.53% from a year prior.
  • Finished Goods hit $3.5 million in Q4 2025 for Cytosorbents, up from $2.3 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $3.5 million in Q4 2025 to a low of $1.7 million in Q4 2024.
  • Median Finished Goods over the past 3 years was $2.1 million (2023), compared with a mean of $2.3 million.
  • Biggest five-year swings in Finished Goods: dropped 10.33% in 2024 and later surged 112.53% in 2025.
  • Cytosorbents' Finished Goods stood at $1.9 million in 2023, then decreased by 10.33% to $1.7 million in 2024, then skyrocketed by 112.53% to $3.5 million in 2025.
  • The last three reported values for Finished Goods were $3.5 million (Q4 2025), $2.3 million (Q3 2025), and $2.4 million (Q2 2025) per Business Quant data.